The most prevalent mutation, G12D KRAS, has been associated with poor patient outcomes and resistance to conventional therapies, highlighting the urgent need for targeted therapies specifically designed to combat this mutation.

Biond is developing a selective first in class anti- KRASG12D biological inhibitor that can specifically block protein-protein interactions.